About roivant sciences ltd - ROIV
Roivant Sciences Ltd. engages in the biopharmaceutical business, which engages in the development of transformative medicine. Its product portfolio includes Vtama, Batoclimab, Brepocitinib, Namilumab, and RVT-2001, which aims to treat psoriasis, atopic dermatitis, thyroid eye disease, and other illnesses. The company was founded by Vivek Ramaswamy on April 7, 2014 and is headquartered in London, the United Kingdom.
ROIV At a Glance
Roivant Sciences Ltd.
50 Broadway
London, Greater London SW1H 0BD
| Phone | 44-207-400-3347 | Revenue | 8.26M | |
| Industry | Pharmaceuticals: Major | Net Income | -299,771,000.00 | |
| Sector | Health Technology | Employees | 721 | |
| Fiscal Year-end | 03 / 2027 | |||
| View SEC Filings |
ROIV Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | 2,326.882 |
| Price to Book Ratio | 4.407 |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | -12.489 |
| Enterprise Value to Sales | 1,912.45 |
| Total Debt to Enterprise Value | 0.007 |
ROIV Efficiency
| Revenue/Employee | 11,456.311 |
| Income Per Employee | -415,771.151 |
| Receivables Turnover | 0.01 |
| Total Asset Turnover | 0.001 |
ROIV Liquidity
| Current Ratio | 18.373 |
| Quick Ratio | 18.373 |
| Cash Ratio | 15.274 |
ROIV Profitability
| Gross Margin | 43.91 |
| Operating Margin | -15,353.547 |
| Pretax Margin | -3,203.123 |
| Net Margin | -3,629.189 |
| Return on Assets | -5.37 |
| Return on Equity | -6.506 |
| Return on Total Capital | -6.468 |
| Return on Invested Capital | -6.377 |
ROIV Capital Structure
| Total Debt to Total Equity | 2.373 |
| Total Debt to Total Capital | 2.318 |
| Total Debt to Total Assets | 1.876 |
| Long-Term Debt to Equity | 2.127 |
| Long-Term Debt to Total Capital | 2.078 |